By:- Team VOH
25 May 2024
Mylab Discovery Solutions is an Indian biotech firm focused on developing & commercializing Molecular, Serological, Immunology, Imaging, Biochemistry and Haematology testing solutions with focus on building Automated POC systems for applications in clinical diagnostics, drug discovery, biomedical research, Agri genomics, animal, and food safety.
Our focus is always on developing solutions that the country will be needing next. With impact-based product development as the cornerstone of our approach, we are constantly striving to introduce affordable and accessible indigenous diagnostics solutions by leveraging ground-breaking innovations. We are committed to empower people to lead healthier lives by discovering diagnostic solutions for the infectious and non-communicable diseases that threaten health of India’s population.
We are committed to approach TB as the key public health issue. At the moment, Mylab has the most comprehensive portfolio for TB globally. We would like to share the bedrock of these offerings. This is combined Point of Care solution developed by our organization represents a significant advancement in tuberculosis (TB) diagnosis and management. By integrating the Mylab PathoDetect MTB-RIF-INH kit with the Compact DX device, we have created a streamlined and efficient system for simultaneous detection of TB and resistance to first-line drugs Rifampicin and Isoniazid. This innovation has several key features and benefits:
• Simultaneous Detection: The Mylab PathoDetect MTB-RIF-INH kit allows for the simultaneous detection of TB and resistance status to Rifampicin and Isoniazid. This enables healthcare providers to quickly identify the appropriate treatment regimen for patients, thereby improving outcomes and reducing the risk of further transmission of drug-resistant TB strains.
• Automation: The Compact DX device automates the entire testing process, from sample preparation to result interpretation. This eliminates the need for manual intervention, reducing the risk of errors and ensuring consistent and reliable results.
• Speed: The streamlined workflow of the Point of Care solution enables rapid turnaround times, with results available within a couple of hours. This facilitates prompt initiation of treatment and reduces the time patients spend waiting for diagnosis, leading to improved patient care and healthcare delivery.
• Robustness: The system is designed to be robust and reliable, capable of operating in rough conditions commonly encountered in resource-limited settings. This ensures that patients in remote or underserved areas have access to accurate and timely TB diagnosis and treatment.
• Detection of Isoniazid Resistance: The Mylab PathoDetect MTB-RIF-INH kit is the only molecular test available that can accurately detect resistance to Isoniazid, a first-line drug for TB treatment. Isoniazid resistance occurs in approximately 11% of all TB-positive patients, leading to treatment failures and prolonged illness due to ineffective therapy. By identifying Isoniazid resistance upfront, healthcare providers can avoid prescribing ineffective medications, thus preventing further exacerbation of drug-resistant TB and improving patient outcomes.
Challenges during development and implementation may have included optimizing the performance of the molecular test, ensuring compatibility and integration with the automated device, and addressing regulatory requirements for approval and deployment. These challenges were likely overcome through rigorous testing, collaboration between multidisciplinary teams, and ongoing refinement of the technology based on feedback from clinicians and end-users.
Looking to the future, healthcare technology holds immense potential for further improving patient care and healthcare delivery. We envision continued innovation in diagnostic technologies, with a focus on point-of-care solutions that are rapid, accurate, and accessible to a wide range of healthcare settings. Additionally, we anticipate advancements in telemedicine and remote monitoring technologies, enabling more personalized and proactive healthcare delivery. Our organization remains committed to driving these advancements through ongoing research and development efforts, with a focus on addressing unmet needs and improving health outcomes for patients worldwide.
16 Jun 2024
16 Jun 2024
16 Jun 2024
16 Jun 2024
16 Jun 2024